Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Prior treatment

• Inability to swallow oral medications

Other illness

• Participants with only locally advanced disease

Other

• Participant has squamous, adenosquamous, neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma
• Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases

• Must be ≥18 years of age
• Must have confirmed diagnosis according to AJCC staging as follows:
  • Metastatic pancreatic adenocarcinoma within 12 weeks prior to screening
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Participants must be treatment naive as follows:
  • First-line PDAC participants will have received no previous systemic anti-cancer therapy
• Must have evidence of measurable disease (at least one target lesion) per RECIST v1.1 criteria
• Adequate organ function, hepatic function, coagulation studies and protocol determined clinical laboratory values